News & Events

SAN DIEGO, CA, March 7, 2023 – Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced that Nancy Whiting, Pharm.D., chief executive officer of Recludix, will present an overview of the company at the virtual Oppenheimer 33rd Annual Healthcare Conference. The company’s presentation will be […]

SAN DIEGO, CA, February 1, 2023 – Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced that Nancy Whiting, Pharm.D., chief executive officer of Recludix, will present an overview of the company at the Guggenheim Healthcare Talks Oncology Conference in New York, NY. The company’s […]

SAN DIEGO, CA, January 6, 2023 – Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced that Nancy Whiting, Pharm.D., chief executive officer of Recludix, will present an overview of the company at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The […]

SAN DIEGO, CA, October 20, 2022 – Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced the appointment of Paul A. Smith, Ph.D., as senior vice president of biology. “Paul has extensive drug discovery experience, including in transitioning therapies from research to clinical development, as […]

SAN DIEGO, CA, September 29, 2022 – Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced the appointment of Matthew Caldemeyer as chief business officer. “We are excited to welcome Matt to our executive leadership team,” said Nancy Whiting, Pharm.D., chief executive officer of Recludix. […]

SAN DIEGO, CA, September 13, 2022 – Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced the appointment of Athena Countouriotis, M.D., as the chairperson of the board of directors. “Athena is both a distinguished biotech business leader as well as a physician and oncologist, […]

SAN DIEGO, CA, January 6, 2022 – Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced the establishment of its scientific advisory board. “We are thrilled to have established a group of distinguished scientific thought leaders as advisors to the company,” said Nancy Whiting, Pharm.D., […]

–Three SH2 domain inhibitor programs targeting STAT3, STAT6 and an undisclosed non-STAT target are underway –Nancy Whiting, Pharm.D., an industry veteran and one of Fierce Pharma’s Fiercest Women in Life Sciences in 2020, named as chief executive officer –Pedigreed senior leadership team and Series A investors disclosed SAN DIEGO, CA, November 15, 2021 – Recludix […]